ATE472554T1 - Aminosäureaustauschmutanten von interleukin 13 - Google Patents

Aminosäureaustauschmutanten von interleukin 13

Info

Publication number
ATE472554T1
ATE472554T1 AT01968131T AT01968131T ATE472554T1 AT E472554 T1 ATE472554 T1 AT E472554T1 AT 01968131 T AT01968131 T AT 01968131T AT 01968131 T AT01968131 T AT 01968131T AT E472554 T1 ATE472554 T1 AT E472554T1
Authority
AT
Austria
Prior art keywords
amino acid
interleukin
hil13
acid exchange
acid residues
Prior art date
Application number
AT01968131T
Other languages
English (en)
Inventor
Waldemar Debinski
Original Assignee
Penn State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Res Found filed Critical Penn State Res Found
Application granted granted Critical
Publication of ATE472554T1 publication Critical patent/ATE472554T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01968131T 2000-08-30 2001-08-24 Aminosäureaustauschmutanten von interleukin 13 ATE472554T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22919400P 2000-08-30 2000-08-30
PCT/US2001/026558 WO2002018422A1 (en) 2000-08-30 2001-08-24 Amino acid substitution mutants of interleukin 13

Publications (1)

Publication Number Publication Date
ATE472554T1 true ATE472554T1 (de) 2010-07-15

Family

ID=22860182

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01968131T ATE472554T1 (de) 2000-08-30 2001-08-24 Aminosäureaustauschmutanten von interleukin 13

Country Status (6)

Country Link
EP (1) EP1315742B1 (de)
JP (1) JP4863150B2 (de)
AT (1) ATE472554T1 (de)
AU (1) AU2001288405B8 (de)
DE (1) DE60142479D1 (de)
WO (1) WO2002018422A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042028A2 (en) * 2003-10-27 2005-05-12 Neopharm, Inc. Il-13 conjugated to an immunogen and uses thereof
WO2006113614A2 (en) * 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Service National Institutes Of Health Methods of treating and preventing inflammatory bowel disease involving il-13 and nkt cells
US9512194B2 (en) 2012-01-27 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Modified IL-13 polypeptides
IN2015KN00329A (de) 2012-08-09 2015-07-10 Univ Leland Stanford Junior
WO2015042706A1 (en) 2013-09-24 2015-04-02 Medicenna Therapeutics Pte Ltd Interleukin-4 receptor-binding fusion proteins and uses thereof
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
CN108883180B (zh) 2016-02-05 2023-07-07 奥里尼斯生物科学私人有限公司 Clec9a结合剂及其用途
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
CA3023883A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
EP3455245A2 (de) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutisches targeting von nichtzellulären strukturen
ES2917000T3 (es) 2016-10-24 2022-07-06 Orionis Biosciences BV Interferón-gamma mutante diana y usos del mismo
MX2019009255A (es) 2017-02-06 2019-11-05 Orionis Biosciences Nv Proteínas quiméricas dirigidas y sus usos.
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
US12274735B2 (en) 2017-10-10 2025-04-15 Medicenna Therapeutics Inc. IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
WO2019148089A1 (en) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Xcr1 binding agents and uses thereof
KR102877915B1 (ko) 2018-02-05 2025-10-29 오리오니스 바이오사이언시즈 인코포레이티드 섬유아세포 결합제 및 이의 용도
US12404497B2 (en) 2018-06-01 2025-09-02 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof
WO2020198665A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Fibroblast activation protein binding agents and use thereof
WO2024236167A1 (en) 2023-05-17 2024-11-21 Morphosys Ag Il-13 receptor alpha 2 binding polypeptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US6296843B1 (en) * 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
WO2001025282A1 (en) * 1999-10-06 2001-04-12 The Penn State Research Foundation Il13 mutants
WO2001034645A2 (en) * 1999-11-11 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Mutated il-13 molecules and their uses

Also Published As

Publication number Publication date
EP1315742A1 (de) 2003-06-04
AU2001288405B8 (en) 2007-06-14
AU8840501A (en) 2002-03-13
DE60142479D1 (de) 2010-08-12
WO2002018422A1 (en) 2002-03-07
EP1315742A4 (de) 2004-08-11
JP2004507264A (ja) 2004-03-11
AU2001288405B2 (en) 2007-05-03
EP1315742B1 (de) 2010-06-30
JP4863150B2 (ja) 2012-01-25

Similar Documents

Publication Publication Date Title
DE60142479D1 (de) Aminosäureaustauschmutanten von interleukin 13
DE69634640D1 (de) Mutierte alpha-amylase enzyme mit erhöhter stabilität
CY1111006T1 (el) Εκριμματαση ασθενειας alzheimer
ATE286907T1 (de) Cytokinin-designiertes lerk-5
NO980976D0 (no) Materialer og fremgangsmåter for å feste og fremvise stoffer på celleoverflater
CY1108998T1 (el) Πρωτεϊνες που δεσμευονται με οστεοπροτεγερινη και υποδοχεις
DE69936312D1 (de) Mutanten von op-1
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
PT973874E (pt) Ensaio enzimatico para a luciferase mutante de pirilampos
CY1109230T1 (el) Ισομεραση συζευγμενου λινελαϊκου οξεος και μια διαδικασια για την παρασκευη συζευγμενου λινελαϊκου οξεος
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
EA200000144A1 (ru) Направленный цитолиз клеток-мишеней, агенты и композиции, вызывающие цитолиз, и соединения, которые можно использовать для получения этих агентов
CY1110868T1 (el) Ελαχιστη αλληλουχια dna που δρα ως μονωτης της χρωματινης και η χρηση της στην πρωτεϊνικη εκφραση
CY1110877T1 (el) Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση
ES8705467A1 (es) Un procedimiento para producir la proteina apoacuorina
HRP20050354B1 (de)
TR200100056T2 (tr) Nörotrofik faktörler
DE60208692D1 (de) Interleukin -18 mutantenproteine, deren herstellung und verwendung
CY1114526T1 (el) Κατασταλτικες πρωτεϊνες μιας πρωτεασης (protease) και χρησεις αυτων
EA199900869A1 (ru) Цитокин-подобный фактор 7 млекопитающих
ATE294855T1 (de) Rna polymerase mutanten mit erhöhter thermostabilität
ATE286139T1 (de) Replikationskompetente anti-tumor vektoren
DE60109430D1 (de) An entzündlichen darmerkrankungen beteiligte gene und deren verwendung
PT1025245E (pt) Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes
ATE337336T1 (de) Nukleinsäuren, die für stichodactylidae chromoproteine kodieren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties